Mednetas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 25,843 | 123,632 | 215,629 | 292,830 | 371,965 | 673,566 | 815,257 | 847,481 |
| Profit before tax | - | - | - | - | - | 282,941 | 269,601 | 289,233 |
| Net profit | 36,629 | 38,871 | 91,665 | 164,423 | 212,072 | 240,330 | 228,613 | 242,679 |
| Equity | 37,652 | 76,523 | 41,082 | 13,064 | 97,013 | 44,767 | 62,590 | 68,912 |
| Liabilities | 32,774 | 50,984 | 52,564 | 69,261 | 48,581 | 92,639 | 1,353,608 | 1,350,031 |
| Non-current assets | 26,667 | 72,405 | 38,748 | 29,179 | 0 | 66,814 | 1,333,430 | 1,388,536 |
| Current assets | 43,578 | 54,582 | 54,453 | 52,790 | 145,594 | 69,333 | 78,143 | 27,289 |
| Total assets | 70,245 | 126,987 | 93,201 | 81,969 | 145,594 | 136,147 | 1,411,573 | 1,415,825 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 173,372 | 154,404 | 164,050 |
| Social insurance contributions | - | - | - | - | - | 59,124 | 84,994 | 92,930 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +378.4% | +74.4% | +35.8% | +27.0% | +81.1% | +21.0% | +4.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 52.1% | 30.6% | 98.4% | 200.6% | 145.7% | 176.5% | 16.2% | 17.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 97.3% | 50.8% | 223.1% | 1258.6% | 218.6% | 536.8% | 365.3% | 352.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 141.7% | 31.4% | 42.5% | 56.1% | 57.0% | 35.7% | 28.0% | 28.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | 42.0% | 33.1% | 34.1% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.9 | 0.7 | 1.3 | 5.3 | 0.5 | 2.1 | 21.6 | 19.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 20,674 | 12,467 | 23,523 | 34,116 | 37,197 | 30,733 | 32,719 | 32,700 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Mednetas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-08-17 | 2023-09-11 | 0.06 |
| 2023-07-24 | 2023-08-13 | 0.06 |
| 2023-05-18 | 2023-05-21 | 8.01 |
| 2023-05-02 | 2023-05-11 | 8.01 |
| 2023-04-27 | 2023-04-28 | 8.01 |
| 2023-04-26 | 2023-04-26 | 6.87 |
| 2023-04-25 | 2023-04-25 | 8.01 |
| 2023-04-19 | 2023-04-24 | 6.87 |
Mednetas - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Mednetas, UAB (code 304628774) is a Private Limited Liability Company operating in Medical specialists activities. In 2025, the company continued to expand moderately, with revenue reaching €847.5K, up 4.0% year on year and 25.8% over two years. This followed €673.6K in 2023 and €815.3K in 2024, showing a steady upward trajectory. Net profit increased to €242.7K in 2025, compared with €228.6K in 2024 and €240.3K in 2023. Profit margin stood at 28.6% in 2025, after 28.0% in 2024 and 35.7% in 2023, indicating solid profitability despite some margin compression versus 2023. Total assets were €1.42M in 2025, broadly unchanged from €1.41M in 2024 but much higher than €136.1K in 2023, reflecting a substantial expansion of the asset base. Long-term assets accounted for €1.39M, while liabilities remained at €1.35M. Equity rose to €68.9K, leaving a low equity ratio of 4.9% and a high debt-to-equity level. ROE was elevated because of the small equity base. Asset turnover was 0.60x, ROA 17.1%, and revenue per employee was €33.9K.